The drug didn’t make the fibrous cap around the plaque thicker, so its protective effect must come from other changes, like less cell death or inflammation.

Pro

Against

Evidence from Studies

Supporting (0)

Community contributions welcome

No supporting evidence found

Contradicting (1)

Community contributions welcome

A cyclic azapeptide ligand of the scavenger receptor CD36/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice

Randomized Controlled Trial

Animal

2023

The study says the drug makes plaques more stable, but it never measured the collagen in the plaque’s protective cap, so we can’t tell if the cap got thicker or not.

Source Study

A cyclic azapeptide ligand of the scavenger receptor CD36/SR-B2 reduces the atherosclerotic lesion progression and enhances plaque stability in apolipoprotein E-deficient mice

Score: 12

DOI: 10.3389/fphar.2023.1204905

Similar Assertions

The drug-treated mice had almost half as many dying cells in their artery plaques, which could mean their plaques are less damaged and more stable.

83%

The drug seemed to make more of the CD36 protein visible in the artery plaques, which might help the body clear dead cells better.

82%

There was a hint that the drug might help turn some immune cells into a less inflammatory type, but the data weren’t strong enough to be sure.

80%

Mice treated with the drug had much smaller dead-cell areas in their artery plaques—almost half as big—which might mean their plaques are less likely to break open.

80%

The drug didn’t lower the mice’s overall cholesterol, so its benefits must come from something else—like reducing inflammation or cell death in plaques.

79%